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Relationship between oral declaration on
adherence to ivermectin treatment and
parasitological indicators of onchocerciasis
in an area of persistent transmission
despite a decade of mass drug
administration in Cameroon
Samuel Wanji1,2* , Jonas A. Kengne-Ouafo1,2, Mathias E. Esum1,2, Patrick W. N. Chounna1,2, Bridget F. Adzemye1,2,
Joan E. E. Eyong2,4, Isaac Jato3, Fabrice R. Datchoua-Poutcheu1,2, Raphael A. Abong1,2, Peter Enyong1,3
and David W. Taylor5
Abstract
Background: Onchocerciasis control for years has been based on mass drug administration (MDA) with ivermectin
(IVM). Adherence to IVM repeated treatment has recently been shown to be a confounding factor for onchocerciasis
elimination precisely in rain forest areas where transmission continues and Loa loa co-exists with Onchocerca volvulus.
In this study, participants’ oral declarations were used as proxy to determine the relationship between adherence to
IVM treatment and parasitological indicators of onchocerciasis in the rain forest area of Cameroon with more than a
decade of MDA.
Methods: Participants were recruited based on their IVM intake profile with the aid of a semi-structured questionnaire.
Parasitological examinations (skin sniping and nodule palpation) were done on eligible candidates. Parasitological
indicators were calculated and correlated to IVM intake profile.
Results: Of 2,364 people examined, 15.5 % had never taken IVM. The majority (40.4 %) had taken the drug 1–3 times
while only 18 % had taken≥ 7 times. Mf and nodule prevalence rates were still high at 47 %, 95 % CI [44.9–49.0 %] and
36.4 %, 95 % CI [34.4–38.3 %] respectively. There was a treatment-dependent reduction in microfilaria prevalence
(rs =−0.986, P = 0.01) and intensity (rs =−0.96, P = 0.01). The highest mf prevalence (59.7 %) was found in the zero
treatment group and the lowest (33.9 %) in the≥ 7 times treatment group (OR = 2.8; 95 % CI [2.09–3.74]; P < 0.001).
Adults with≥ 7 times IVM intake were 2.99 times more likely to have individuals with no microfilaria compared to the
zero treatment group (OR = 2.99; 95 % CI [2.19–4.08], P < 0.0001). There was no clear correlation between treatment
and nodule prevalence and intensity.
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* Correspondence: swanji@yahoo.fr
1Parasite and Vectors Research Unit, Department of Microbiology and
Parasitology, University of Buea, P.O.Box 63, Buea, Cameroon
2Research Foundation for Tropical Diseases and Environment, P.O.Box 474,
Buea, Cameroon
Full list of author information is available at the end of the article
© 2015 Wanji et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Wanji et al. Parasites & Vectors  (2015) 8:667 
DOI 10.1186/s13071-015-1283-6
(Continued from previous page)
Conclusion: Adherence to ivermectin treatment is not adequate in this rain forest area where L. loa co-exists with O.
volvulus. The prevalence and intensity of onchocerciasis remained high in individuals with zero IVM intake after more
than a decade of MDA. Our findings show that using parasitological indicators, reduction in prevalence is IVM intake-
dependent and that participants’ oral declaration of treatment adherence could be relied upon for impact studies. The
findings are discussed in the context of challenges for the elimination of onchocerciasis in this rain forest area.
Keywords: Oral declaration, Adherence, Ivermectin, Parasitological indicators, Transmission, MDA, Onchocerciasis
Background
Onchocerciasis is a debilitating vector-borne disease
caused by the parasite Onchocerca volvulus. It is transmit-
ted by black flies of genius Simulium [1, 2]. The disease is
a public health and socio-economic threat in many Afri-
can countries [3–5]. It has been estimated that 36 million
people are infected [6] and 86 million people live in high
risk areas in the African programme for Onchocerciasis
control (APOC) countries [7]. Onchocerciasis is the
second-leading infectious cause of blindness worldwide,
being responsible for about 500,000 cases of blindness [8,
9] Using the Rapid Epidemiological Mapping of Oncho-
cerciasis (REMO), different foci have been mapped out in
Cameroon [10] including the rain forest of South West
Cameroon which is co-endemic with loiasis [11].
Since the creation of APOC in 1995, the control of on-
chocerciasis has been based on annual mass drug distri-
bution (MDA) in most endemic countries [12]. This was
done by establishing the Community-Directed Treat-
ment with ivermectin (CDTI). With CDTI, drug distri-
bution is carried out by selected community members
who share the drug annually and make records for even-
tual evaluation of the programme if treatment registers
are well kept. The main objective of APOC was to re-
duce the prevalence and transmission of onchocerciasis
to a point where the disease will no longer be a public
health problem in countries not previously covered by
the Onchocerciasis Control Programme (OCP). A single
annual dose of ivermectin can clear microfilariae from
the skin and consequently reduce morbidity associated
with the infection. Although ivermectin is an extremely
effective microfilaricide, many years of administration
are required to kill adult worms. Hence onchocerciasis
elimination depends to a great extent to adherence to re-
peated annual treatment with ivermectin [13, 14]. Ad-
herence or compliance refers to the extent to which a
patient acts in accordance with the prescribed interval
and dosing regimen [15]. In some contexts, the two
terms are used interchangeably however, the main differ-
ence is that adherence requires the patient’s agreement
to the recommendations [16]. Since with CDTI, partici-
pants are not forced to take the drug but instead are
sensitised and educated on its benefits, the term adher-
ence seems more relevant.
The feasibility and purported elimination of onchocercia-
sis has been demonstrated in some savannah regions of Af-
rica after 15-17 years of treatment [17–20]. However, the
situation is different in rain forest areas as demonstrated
by Wanji and colleagues [21] where transmission of the
parasite has continued even after a decade of MDA. This
persistent transmission could be due to low adherence to
ivermectin treatment because of fear of severe adverse ef-
fects [14, 22–24]. It could also be due to ecological factors
that strongly favour transmission of O. volvulus [21].
In a multi-site study evaluating five CDTI projects in
Nigeria and Cameroon, where at least eight annual IVM
distributions had taken place, it was demonstrated that
over one-quarter of age-eligible people in study commu-
nities were low compliers [25] and thus serve as a reser-
voir for continued transmission of onchocerciasis [14,
26]. Reports of the impact of adherence to ivermectin
treatment on parasitological indicators are scarce or ab-
sent from rain forest areas. This may be explained by
the absence or poor quality of treatment registers. Re-
cords kept by community drug distributors (CDDs) are
often incomplete and therefore considered unreliable to
assess adherence [27].
In this study, participants’ oral declarations were used
as proxy to determine the relationship between adher-
ence to ivermectin treatment and parasitological indica-
tors of onchocerciasis in the rain forest area of
Cameroon with more than a decade of CDTI. This ap-
proach has been used in a small number of other studies
[13, 14, 27].
Methods
Study site
The study was carried out in communities in the Konye,
Mamfe, Eyumojock and Kumba health districts, which
are located in three different hydrographical basins situ-
ated in the rain forest zone of the South West,
Cameroon and previously described by Wanji and col-
leagues [21]. The climate of the study sites is of the
equatorial type. The temperatures are high, ranging from
25 to 32 °C. The vegetation is secondary forest resulting
from the degradation of the dense humid forest for agri-
cultural activities. The tributaries of the Rivers Mungo
and Meme (Konye and Kumba) and the tributaries of
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River Manyu (Mamfe and Eyumojock) serve as breeding
sites for Simulium spp. in these areas.
Study population and design
This cross-sectional study was designed to assess the rela-
tionship between ivermectin treatment adherence and
parasitological indices of onchocerciasis [21]. Community-
Directed Treatment with Ivermectin (CDTI) had been
going on in the study area for 10 to 12 years with geo-
graphical coverage varying between 95–100 % and thera-
peutic coverage generally above 65 % [21]. Some cases of
severe adverse reactions had been reported in this area at
the onset of ivermectin treatment [28]. Participants en-
rolled in this study were from communities found around
the three drainage basins. They were of both sexes and
aged 5-94 years. They had not taken any filaricide medica-
tion for one year prior to sample collection but had been
resident in the area for at least five years. Participants were
recruited with the aid of a structured questionnaire and all
had given their consent or assent (children) to take part in
the study.
In addition to demographic data, questions were asked
as to whether individuals had ever taken ivermectin and
the number of times and the last time (s)he had taken
the drug. Comparison of the records of the oral declara-
tions with the records of the CDDs treatment registers
was not done because the latter were incomplete and
therefore considered unreliable. Eligible participants
were categorised by the number of times they had taken
the drug (zero; 1 – 3; 4 – 6; and, ≥ 7 times). All were
subjected to a parasitological examination and the re-
sults obtained correlated with their treatment profiles.
Only participants who had not taken any filaricide medi-
cation for the past one year were enrolled in the study
to avoid the situation where a reduction in mf load could
be due to recently administered drug. Recruitment of this
cohort was helped by beginning the study before the large
scale annual distribution of ivermectin. Information on
the CDTI indicators (geographical and treatment cover-
ages) were obtained from the National Onchocerciasis
Control Programme through their regional branches in
the south west. Parasitological surveys were carried out in
April and July of 2011 and 2012. Mf and nodule preva-
lence and Mf and nodule intensity were recorded against
ivermectin treatment profiles.
Ethical considerations
Study was approved by the Cameroon National Ethics
Committee and the Ministry of Public Health. Individ-
uals recruited as volunteers were informed of the study
protocol, and the importance of the study for the im-
provement of control measures. Participants were also
told about potential risks to which they could be ex-
posed and the benefits they could receive during and
after the study. Only those who indicated their consent
by signing a consent or assent form were recruited for
the study. Recruitment was done based on the approach
described previously by Kengne-Ouafo et al. [29] after a
rapid ethical assessment undertaken in the North-West
Cameroon to deteremine the level of individual and
community knowledge of ethical issues related to bio-
medical research. All participants’ information collected
during the course of the research were kept on a pass-
word protected database and were strictly confidential.
Parasitological examinations
Parasitological examinations were carried out as previ-
ously described by Wanji et al. [21]. Nodule palpation
and skin snipping were carried out to determine the
presence of the parasite. This was done on partially un-
dressed patients following Rapid Epidemiological Assess-
ment (REA) guidelines [6, 7, 10, 30]. Attention was paid to
bony prominences of the iliac crest, torso, knees, arms,
head and the upper trochanter of the femur. The number
of nodules found and their position were recorded.
From each patient, 2 skin biopsies, one from each
upper iliac crest were taken using a sharp sterile sclera
punch (CT 016 Everhards 2218-15 C, Germany). The bi-
opsies were immediately placed into physiological saline
in separate wells of a 96-well culture plate. The corre-
sponding well numbers were reflected on the partici-
pant’s form. The plates were sealed with parafilm to
prevent any spill over or evaporation. Observation and
microfilaria count was done using an inverted micro-
scope (Motic AE21) at magnification of 10× 24 h later
[21, 31, 32]. Microfilaria count was expressed as mf/skin
snip (ss).
Data analysis
Data collected were entered in a template created in EPI
INFO 6 (version 6) and were analysed using SPSS 20
(Software SPSS INC, Chicago, IL, USA) and Microsoft
Excel 2013. Individuals were selected and categorised by:
(i) sex (male and female); (ii) age groups [children
(<20 year-old) and adults (≥20 year-old)]; (iii) ivermectin
or IVM intake defined as the number of times a partici-
pant had taken ivermectin (zero, i.e. have never taken
ivermectin; 1-3 treatments; 4-6 treatments; and ≥7 treat-
ments); (iv) microfilarial load (zero, i.e. no mf load; 1–50
mf/ss; 51–100 mf/ss; and ≥ 100 mf/ss); (v) nodule num-
ber (0, 1, 2, ≥3). Adults were defined as individuals
20 year-old and above because this age group is used in
the computation of the community microfilarial load
(CMFL). Those of the < 20 year-old age group were iden-
tified as children, and could not be split further because
of the limited number of persons within the study co-
hort. CMFL was expressed as the geometric mean. The
intensity of infection in other groups or categories was
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referred to as Williams mean microfilaria density
(WMMfD) as reported previously [21]. The calculation
was done using the log (x +1) transformation, where x is
the individual microfilaria load [10]. Contingency tables
were used to express the association between variables.
The Chi-square test were also used to compare the
prevalence rates of infection between categories. Student
t-test and ANOVA were used to compare means be-
tween sexes, age groups and IVM intake groups. Spear-
man’s rank correlation was used to show the association
between IVM intake and Mf prevalence; and intensity.
Binary logistic regression analysis was used to check
whether IVM intake was a significant factor in oncho-
cerciasis prevalence and intensity reduction. All the stat-
istical tests were performed at a 5 % significance level.
Results
Study population characteristics
A total of 2,364 (1,269 males and 1,095 females) partici-
pants were enrolled in the study. The mean age of the
study participants was 35.9 years ranging from 5 to
100 years. The study participants were composed of 477
Children [<20 year-old] and 1,887 adults [20 year-old
and above).
Ivermectin intake profile of the study population
A total of 1,997 participants had taken ivermectin at
least once out of the 10–12 rounds of distribution mak-
ing an overall adherence rate of 84.47 %. Of the 2,364 in-
dividuals examined, 367 (15.53 %) had never taken
ivermectin, 956 (40.41 %) had taken between 1-3 times,
615 (26.02 %) had taken between 4-6 times and 426
(18.0 %) had taken ≥ 7 times. There was a significant dif-
ference in the frequency distribution of participants be-
tween IVM intake groups (Table 1, P = 0.031). The
majority of children (66.2 %) had taken ivermectin 1-3
times compared to 33.9 % for adults. However just few
children/adolescents (1.5 %) had received the drugs
more than 7 times compared to 22.2 % for adults.
Sex did not appear to be a critical factor influencing
IVM intake: of 1,269 men who took part in the study,
211 (16.6 %) had never taken ivermectin and 156/1,095
(14.2 %) females had never taken the drug (P = 0.1245).
The same trend was seen in all the treatment groups
(Table 1, P > 0.05).
O. volvulus infection in the study population
Microfilaria and nodule prevalence
Of 2,364 persons that took part in the study, 1,110
(47.0 %, 95 % CI [44.9–49.0 %]) were mf positive
(Table 2). Although more males were infected 48.6 %,
95 % CI [45.8–51.3 %] than females 45.0 %, 95 % CI
[42.0–47.9 %], the difference was not significant (P =
0.08). Similar observations were made for adults (P =
0.173) and children (P = 0.246). Mf prevalence was rela-
tively higher in children than adults (49.7 %, 95 % CI
[45.2–54.1 %] vs 46.3 %, 95 % CI [44.0–48.5 %]; P =
0.181; Table 2).
The overall nodule prevalence was 36.4 %, 95 % CI
[34.4–38.3 %]. Nodules were significantly more prevalent
in males than in females (40.2 %, 95 % CI [37.5–42.9 %]
vs 32.0 %, 95 % CI [29.2–34.7 %]; P < 0.001; Table 2). As
observed in the case of mf prevalence, nodule prevalence
was higher in males than in females, both in children
and adults (P = 0.046 and P < 0.001, respectively). Nod-
ules were rather more prevalent in adults than in chil-
dren (P < 0.001; Table 2).
Microfilaria and nodule intensity
The overall Williams mean mf density (WMMfD) was
4.8. The infection was more intense in males than in fe-
males, both in children and adults (Table 2, P < 0.001).
The WMMfD was higher in children than in adults but
the difference was not significant (Table 2; P = 0.454). Of
the examined population, 1,010 (42.7 %) had mf load
Table 1 Ivermectin intake based on oral declarations in the study population by age and sex
IVM INTAKE
Gender 0 [1–3] [4–6] >7 Total
Children Male 42 (16.2) 179 (69.1) 35 (13.5) 3 (1.2) 259
Female 40 (18.3) 137 (62.8) 37 (17.0) 4 (1.8) 218
Total 82 (17.2) 316 (66.2) 72 (15.1) 7 (1.5) 477 P = 0.508
Adults Male 169 (16.7) 347 (34.4) 265 (26.2) 229 (22.7) 1010
Female 116 (13.2) 293 (33.4) 278 (31.7) 190 (21.7) 877
Total 285 (15.1) 640 (33.9) 543 (28.8) 419 (22.2) 1887 P = 0.029
Total Male 211 (16.6) 526 (41.4) 300 (23.7) 232 (18.3) 1269
Female 156 (14.2) 430 (39.3) 315 (28.8) 194 (17.7) 1095
Total 367 (15.5) 956 (40.4) 615 (26.0) 426 (18.0) 2364 P = 0.031
IVM Ivermectin
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between 1–50 mf/ss, 51 (2.2 %) between 51–100 mf/ss
and 49 (2.1 %) greater than 100 mf/ss. These proportions
were slightly higher in males than in females (Table 3).
There was a significant difference in the proportions of
individuals between the various mf load groups (P =
0.017) but not within groups (P > 0.05). This profile was
seen both in children and adults (Table 3). The majority
(53.0 %) of the study population had no mf in their
biopsies.
The mean number of nodule among positive individ-
uals was 1.64 and ranged between 1–11. Only 5.6 % of
the study population had more than 3 nodules compared
to 63.6 %, 21.8 % and 8.9 % with 0, 1 and 2 nodule, re-
spectively. The same trend was observed among males
and females, both in children and adults (Table 4, P <
0.001).
Influence of Treatment on O. volvulus infections
Effect of ivermectin treatment on O. volvulus mf and
nodule prevalence
Globally, there was a negative association between O.
volvulus mf prevalence and the ivermectin intake (rs
= -0.99, P = 0.01). The highest mf prevalence (59.7 %)
was found in the zero treatment group (i.e. people who
had never taken ivermectin). This prevalence gradually
declined with treatment to 33.9 % in the ≥ 7 times treat-
ment group (OR = 2.8; 95 % IC [2.09–3.74]; P < 0.001).
This trend showed that the more ivermectin is taken the
lower the prevalence (Fig. 1). However, no such associ-
ation was found in children (Fig. 1).
In contrast, no association was found between the
overall nodule prevalence and IVM treatment. Nodule
prevalence for individuals who had never received the
drug was similar to that of those who had received it 7
times or more (38.1 % vs 38.3 %; Fig. 2) and there was
no significant difference in overall nodule prevalence be-
tween the different IVM intake groups (P = 0.568). The
same observation was made for children (P = 0.09).
However, there were significant variations (with no
trend) in nodule prevalence with respect to IVM intake
for adults (P = 0.02, Fig. 2).
Effect of ivermectin treatment on O. volvulus mf and
nodule intensity
The intensity of infection (WMMfD) was observed to be
high in the group of people who had never taken Iver-
mectin with an overall mean of 7.46. Children had the
highest WMMfD (9.84) in this IVM intake group (Fig. 3).
Table 2 Observed parasitological indices of onchocerciasis in the study population by age and sex
Gender Number examined Microfilaria prevalence Nodule prevalence WMMfD (Mf/ss)
Children Male 259 135 (52.1) 74 (28.6) 5.62
Female 218 102 (46.8) 45 (20.6) 4.75
Total 477 237 (49.7) 119 (24.9) 5.22
Adults Male 1010 482 (47.7 436 (43.2) 5.52
Female 877 391 (44.6) 305 (34.8) 3.97
Total 1887 873 (46.3) 741 (39.3) 4.72
Total Male 1269 617 (48.6 510 (40.2) 5.54
Female 1095 493 (45.0) 350 (32.0) 4.11
Total 2364 1110 (47.0 860 (36.4) 4.82
WMMfD Williams mean microfilaria density
Table 3 Proportions of individuals in defined mf load groups by age and sex
Mf load group
Gender 0mf 1-50mf 51-100mf >100mf Total
Children Male 124 (47.9) 118 (45.6) 9 (3.5) 8 (3.1) 259
Female 116 (53.2) 94 (43.1) 4 (1.8) 4 (1.8) 218
Total 240 (50.3) 212 (44.4) 13 (2.7) 12 (2.5) 477 P = 0.434
Adults Male 528 (52.3) 431 (42.7) 27 (2.7) 24 (2.4) 1010
Female 486 (55.4) 367 (41.8) 11 (1.3) 13 (1.5) 877
Total 1014 (53.7) 798 (42.3) 38 (2.0) 37 (2.0) 1887 P = 0.056
Total Male 652 (51.4) 549 (43.3) 36 (2.8) 32 (2.5) 1269
Female 602 (55.0) 461 (42.1) 15 (1.4) 17 (1.6) 1095
Total 1254 (53.0) 1010 (42.7) 51 (2.2) 49 (2.1) 2364 P = 0.017
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There was a significant decrease in WMMfD with iver-
mectin intake irrespective of age. The greater the num-
ber of times an individual had taken the drug, the lower
his or her WMMfD (F = 18.99; P < 0.001). There was a
negative correlation between IVM intake and intensity
of infection (rs = -0.96, P < 0.001, rs = -1.00, P = 0.01, and
rs = -0.99, P = 0.01 for the overall study population,
adults and children, respectively; Fig. 3).
Like with mf prevalence, no association with trend was
found between IVM intake and the proportion of
individuals with different mf loads for children (Fig. 4).
However, the proportion of people with no microfilariae
in the skin was found to increase with IVM intake in
adults and overall study population (Figs. 5 and 6). Of
the 285 (15.1 %) adults who had never taken the drug,
40.0 % had no microfilaria. This proportion gradually in-
creased with IVM intake to 66.6 % for those who had
taken the drug 7 times and above (Fig. 5, P < 0.0001). Lo-
gistic regression revealed that adults who had had IVM
7 times or more were 2.99 times more likely to have
Table 4 Frequency distribution of the study population in defined nodule load groups by age and sex
Number of nodule
Gender 0 1 2 >3 Total
Children Male 185 (71.4) 54 (20.8) 12 (4.6) 8 (3.1) 259
Female 173 (79.4) 29 (13.3) 12 (5.5) 4 (1.8) 218
Total 358 (75.1) 83 (17.4) 24 (5.0) 12 (2.5) 477 P = 0.123
Adults Male 574 (56.8) 244 (24.2) 119 (11.8) 73 (7.2) 1010
Female 572 (65.2) 189 (21.6) 68 (7.8) 48 (5.5) 877
Total 1146 (60.7) 433 (22.9) 187 (9.9) 121 (6.4) 1887 P = 0.001
Total Male 759 (59.8) 298 (23.5) 131 (10.3) 81 (6.4) 1269
Female 745 (68.0) 218 (19.9) 80 (7.3) 52 (4.7) 1095
Total 1504 (63.6) 516 (21.8) 211 (8.9) 133 (5.6) 2364 P < 0.001
0
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80
0 [1-3] [4-6]
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n= 2364
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Fig. 1 Effect of ivermectin treatment on O. volvulus mf prevalence in the study population. (Number of people examined per IVM intake groups
written in the order children, adults (overall): [0 time] = 82, 285 (367); [1-3 times] = 316, 640 (956); [4-6 times] = 72, 543 (615); [≥7 times] = 7, 419
(426). Bars represent the 95 % margin of error. Significance level set at 5 %
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individuals with no mf compared to the zero IVM intake
group (OR = 2.99; 95 % IC [2.19–4.08], P < 0.0001;
Table 5). The opposite was observed with infected indi-
viduals (Fig. 5). The proportion of individuals with mf
load ranging from 1–50 mf/ss decreased from 50.9 % in
the untreated group to 31.7 % in the ≥7 treatment round
groups (OR = 0.45; 95 % IC [0.33–0.61], P < 0.0001;
Table 5). The same trend was observed with [51–100
mf] and [>100 mf] groups (OR = 0.15; 95 % IC [0.05–
0.45], P = 0.001; and OR = 0.22; 95 % IC [0.06–0.82], P =
0.025, respectively; Table 5; Fig. 5). This relationship was
also found with the entire study population (Table 6;
Fig. 6) but not with children (Fig. 4).
No clear relationship between treatment and nodule
intensity was found. Of 1,504 individuals with zero nod-
ules, 61.9 % had never taken ivermectin. This proportion
was similar for all the other IVM intake groups (P =
0.168). The same observation was made with people
with nodules. For individuals with > 7 times IVM intake,
6.3 % had > 3 nodules, this proportion was not signifi-
cantly different from 8.7 % that of people who had never
taken IVM (P = 0.254, Fig. 7).
Discussion
This is the first study designed to assess the use of com-
munity members’ oral declaration on ivermectin intake
to determine the impact of treatment on parasitological
indicators of onchocerciasis in the rain forest area of
Africa where Loa loa co-exists. This study has shown
adherence to treatment to be inadequate in the study
area; the prevalence of the disease based on the mf pres-
ence remained high (47.0 %) after more than a decade of
mass treatment with ivermectin. It has also shown a
negative association between ivermectin intake and dis-
ease prevalence as well as intensity. Previous studies
have demonstrated long term treatment with ivermectin
to be associated with remarkable reduction in disease
prevalence and intensity [17–19], however none of these
studies analysed the data in relation to individuals’ IVM
intake. Individuals who declared not to have taken Iver-
mectin, or those who declared to have taken it just few
times, were those with higher prevalence and intensity
of infection. Therefore, the parasitological data validated
the information from interview. This was an indication
of the reliability of participants’ oral declarations. Others
studies have used this approach to assess the barriers to
coverage and compliance to MDA for lymphatic filariasis
[14, 27] and the effect of adherence on the impact of
MDA for elimination of lymphatic filariasis [13]. Treat-
ment registers are not always available for information to
be retrieved from [27]. In our setting, registers are kept at
two different levels (health system and community).
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Normally, each year just before mass drug distribution,
the health system gives registers out to community drug
distributors (CDDs). CDDs share the drugs, fill the regis-
ters and send them back to the health system. However,
this is not always the case. More often than not, some
CDDs fail to submit completed registers to the health sys-
tem and this causes a major problem of register availabil-
ity. Registers kept at the community level sometimes are
not properly handled and this constitutes another chal-
lenge, i.e. that of the quality of retrieved registers. Some
registers are returned with missing pages or pages not
properly filled, making the exploitation of the data difficult
and unreliable [27]. This study has demonstrated that
when unavailable (or unreliable), registers could be
bypassed by relying on community members’ oral declar-
ation of IVM intake as a proxy to assess adherence to
treatment.
In the present investigation, there was a lukewarm at-
titude towards ivermectin in the study area. Of the ex-
amined participants, up to 15.5 % had never taken the
drug. The majority had taken the drug just 1–3 times
out of the 10 and 12 rounds of ivermectin mass distribu-
tion. Moreover, only 18 % of the study population had
received IVM 7 times or more. This proportion was very
small in children (1.5 %) and could be related to the fact
that they had not had exposure to the same number of
MDA as adults. These low adherences in meso- and hy-
perendemic areas (as in the present setting) may consti-
tute a potential reservoir of onchocerciasis infection that
could hinder efforts to control the disease [13]. It re-
mains unclear whether ivermectin treatment can be
halted if the parasite reservoir has not been completely
eradicated [33]. This is a, if not the critical issue to re-
solve since MDA against onchocerciasis requires at least
15 years to achieve elimination [12, 34].
The low adherence observed in this study could be at-
tributed to fear of side effects as reported by many au-
thors [13, 14, 26]. Besides itching, it has been shown
that people co-infected with Loa loa and having high L.
loa mf load develop encephalopathy following ivermec-
tin treatment [14, 22–24]. Such manifestations were re-
ported at the onset of mass ivermectin treatment in our
setting [28]. People remain unwilling to accept IVM
treatment due to the risk of side effects [26, 35].
Males stuck to the treatment regime relatively more
than females and adults more than children. These find-
ings corroborate those of Brieger et al. [25] who re-
ported age and sex as factors explaining variations in
adherence to IVM treatment. Communities with low ad-
herence indicate a low level participation of the commu-
nities in CDTI and possibly difficulties in eradication
efforts whereas a high adherence would indicate high
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level of community participation in drug distribution and
administration leading to possible decrease in microfilaria
prevalence rates and loads, ultimately meeting APOC
objectives.
The prevalence of onchocerciasis in our study area
was still high 47.0 % for mf and 36.4 % for nodules des-
pite a decade of ivermectin treatment. This can be justi-
fied by the low adherence found in the study areas. In
addition to high pre-control endemicity levels and high
vectorial capacity reported in the area [36–38], the per-
ennial presence of ecological factors, such as fast flowing
rivers that strongly favour the breeding and development
of the black fly, help maintain continuous transmission
and hence high prevalence of infection [21].
Slightly more males were infected than females. This is
in line with findings of Moyou et al. [39] and could be
linked to their daily activities, i.e. cocoa and palm farm-
ing, which are the main occupation of males and source
of income in our study area. Another reason could be
the fact that men prefer working with exposed bodies
and are thus prone to more bites than (covered) females.
Hormonal differences between the sexes have been
suggested to account for the relatively higher resistance
of females relative to males under similar ecological con-
ditions [39, 40]. The mf prevalence and WMMfD in
children were relatively higher than in adults. Children’s
life style involves playing around the rivers, bushes and,
above all, they have no sense of protection of the body
with clothing from exposure to fly bites. Duke & Moore
[41] reported these findings many years ago and it seems
to still be the case particularly with children living in re-
mote areas.
Ivermectin treatment has reduced the endemicity of
onchocerciasis in the study area from a pre-treatment
mf prevalence and intensity of 92.7 % and 53.6 mf/ss
[39] to 47 % and 4.82 mf/ss respectively. These findings
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show that if adherence to ivermectin treatment is main-
tained in communities, parasitological indicators of on-
chocerciasis would drastically reduce. In this study,
individuals who had never taken the drug were found to
have a significantly higher mf prevalence (58.9 % overall
and 60 % for adults) compared to (33.8 % overall and
33.3 % for adults) for those who had taken the drug ≥ 7
times. The same trend was found with the WMMfD.
There was a significant negative association between the
above-mentioned indicators and IVM intake. Our results
clearly show the important influence of IVM treatment
adherence on residual infection rates after MDA. It was
not surprising that residual infection rates were highest
in people who reported that they had never taken MDA.
Although 1–3 rounds of ivermectin can clear the skin of
microfilariae, 7 or more rounds of MDA had more signifi-
cant effect on mfs. Similar results have been reported from
a study on the effect of adherence on the Impact of MDA
for Elimination of Lymphatic Filariasis in Egypt [13].
These observations highlight the importance of adher-
ence for MDA and the following could be deduced:
(i) The elimination of the disease in an area will de-
pend to a great extent to the proportion of high adher-
ents relative to that of low adherents as they represent a
disease reservoir for the community [14, 25]. Moreover,
children who have never taken IVM were found to have
the highest intensity of infection among the study popu-
lation and as such constituted a danger for the commu-
nity. This risk is further heightened because those under
5 years are excluded from MDA programmes. Their life
style has previously been described as a factor favouring
transmission [41].
(ii) Oral declaration on IVM intake could be used as
proxy to assess the impact of treatment at individual
40
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level when registers are lacking. Our results revealed
that in cohorts that have received ivermectin 7 times or
more, there is a higher likelihood that more than 60 %
will be without mf in the skin compared to 44 % in the
pool with zero IVM intake (Fig. 4). This implies that
knowledge of treatment adherence in a community
would give a rough estimate of the endemicity of the
disease in that community, or area.
If such a study is carried out in different rain forest
areas, a mathematical model could be developed for the
prediction of the proportion of healthy (with no microfil-
aria) versus infected individuals in the community based
on IVM intake. This would be a very helpful and non-
invasive approach to rapidly delineate areas in great needs
of alternative strategies for the elimination of onchocercia-
sis in case that a macrofilaricide was adopted for mass
treatment for onchocerciasis. Rapid assessment proce-
dures have been useful for the identification of priority
communities for the Ivermectin MDA (REA/REMO) or
communities or regions at risk for ivermectin MDA be-
cause of the presence of Loa loa. [6, 7, 10, 30, 42–45].
Although there was a significant reduction in the pro-
portion of infected people with IVM intake, people with
high mf load (>50 mf/ss) were found in all IVM intake
groups. This persistent high mf load, even in individuals
with more than 7 rounds of treatment, could be linked
to the way the drug was taken. Those people may have
been taken the drug in a discontinuous manner and by
so doing facilitate mf load to build up before a second
treatment is taken. Another reason could be a high pre-
treatment endemicity level in addition to the presence of
reservoir of infection (non-adherents and children under
5 years). Pre-treatment mf prevalence and intensity were
demonstrated to be as high as 92.7 % and 53.6 mf/ss in
our setting respectively [39].
In addition to adherence rates, the ONCHOSIM pre-
diction model for onchocerciasis elimination takes into
account variability in vectorial capacity and pre-control
endemicity. It stipulates that the higher the pre-control
endemicity level, the longer the time required to achieve
disease elimination [12, 34]. This might be the case in
the area surveyed [21].
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Many authors have suggested a twice per year treat-
ment strategy accompanied by an increase in therapeutic
coverage to at least 85 % in areas with continuous trans-
mission after several years of control efforts using Iver-
mectin [21, 46]. This strategy can lead up to four rounds
of treatment yearly and has contributed tremendously to
the elimination of onchocerciasis transmission in some
settings [47–49]. This approach does not only reduce
transmission but also reduces the number of years of
treatment needed to achieve elimination of onchocercia-
sis [20, 34]. In an area where the perceived fear of SAEs
is well rooted in the population, the biannual treatment
with ivermectin may not be of significant impact. This
might be the case in the south west region of Cameroon,
where the systematic non-adherence to ivermectin
coupled to low adherence sum up to more than 60 % of
Table 5 Odds of having adults with defined mf loads in the different IVM intake groups (Adults only)
Odds IVM intake (Rounds) Number examined Number confirmeda OR (95 % confidence interval) P value
Odds of having people
with 0 mf load
[0] 285 114 Reference
[1–3] 640 296 1.29 [0.97–1.71] P = 0.078
[4–6] 543 325 2.23 [1.67–2.99] P < 0.0001
≥7 419 279 2.99 [2.19–4.08] P < 0.0001
Odds of having people
with 1–51 mf load
[0] 285 145 Reference
[1–3] 640 312 0.91 [0.69–1.21] P = 0.55
[4–6] 543 208 0.59 [0.45–0.80] P = 0.001
≥7 419 133 0.45 [0.33–0.61] P < 0.0001
Odds of having people
with 51-100 mf load
[0] 285 17 Reference
[1–3] 640 12 0.3 [0.14–0.]64 P < 0.002
[4–6] 543 5 0.14 [0.05–0.4] P < 0.0001
≥7 419 4 0.15 [0.03–0.4] P = 0.001
Odds of having people
with >100 mf load
[0] 285 9 Reference
[1–3] 640 17 0.99 [0.45–2.2] P = 0.98
[4–6] 543 5 0.28 [0.09–0.86] P = 0.02
≥7 419 3 0.22 [0.06–0.82] P = 0.025
aNumber of individuals identified in each mf load group with respect to IVM intake
Table 6 Odds of having people with defined mf loads in the different IVM intake groups (Overall study population)
Odds IVM intake (Rounds) Number examined Number confirmeda OR (95 % confidence interval) P value
Odds of having people
with 0 mf load
[0] 367 151 Reference
[1–3] 956 464 1.35 [1.05–1.72] P = 0.016
[4–6] 615 357 1.98 [1.52–2.57] P < 0.001
≥7 426 282 2.85 [2.09–3.70] P < 0.001
Odds of having people
with 1-51 mf load
[0] 367 178 Reference
[1–3] 956 451 0.94 [0.75–1.21] P = 0.66
[4–6] 615 244 0.70 [0.54–0.90] P = 0.007
≥7 426 137 0.50 [0.37–0.67] P < 0.001
Odds of having people
with 51-100 mf load
[0] 367 24 Reference
[1–3] 956 16 0.24 [0.13–0.47] P < 0.001
[4–6] 615 7 0.16 [0.70–0.38] P < 0.001
≥7 426 4 0.35 [0.04–0.39] P < 0.001
Odds of having people
with >100 mf load
[0] 367 14 Reference
[1–3] 956 25 0.67 [0.34–1.32] P = 0.251
[4–6] 615 7 0.29 [0.11–0.72] P = 0.008
≥7 426 3 0.18 [0.05–0.63] P = 0.007
aNumber of individuals identified in each mf load group with respect to IVM intake
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the population. In such situation, alternative treatment
may be required as ivermectin alone may never lead to
the elimination of onchocerciasis. Several alternative
strategies can be envisaged in this situation. The first
one could be the test and treat strategy in which, the
population is screened for onchocerciasis and those
found positive for O. volvulus microfilariae are treated
with a macrofilaricide drug. The choice of such macrofi-
laricide drug deserves an important consideration. It
should kill the adult O. volvulus, without killing drastic-
ally the L. loa microfilariae. Drugs that deplete Wolba-
chia spp., the endosymbionts found in several filarial
species, have those properties [50–52]. The non-effect
on L. loa microfilariae are justified by the absence of
Wolbachia spp. from L. loa [53]. Antibiotics of tetracyc-
line family have been demonstrated in several studies to
efficiently kill adult O. volvulus [50, 51, 54–56] with no
effect on L. loa microfilariae [51, 53]. Indeed, Doxycyc-
line, has been successfully administered at large scale
level for the treatment of onchocerciasis in area of co-
endemicity of L. loa in Cameroon in a pilot study, with a
high treatment adherence from the population, signifi-
cant impact on the parasitological indicators of oncho-
cerciasis and lack of severe adverse events [57, 58]. The
second alternative strategy option that could be envisaged
in this rain forest area of south west Cameroon is the vec-
tor control, targeting larvae of Simulium spp. in the breed-
ing sites. The rain forest area of South west Cameroon is
characterised by numerous rivers, getting their sources
from the flank of mountains and flowing fast down the
hills, constituting excellent breeding places for S. squamo-
sum and S. yahense [21]. More important is the fact that
the level of water from those rivers is maintained suffi-
ciently high during dry season to allow continuous breed-
ing throughout the year. This is an important consideration
as the epidemiological implications of the continuous
breeding of vectors is the high annual transmission po-
tential which ensures that even residual microfilariae of
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O. volvulus in the skin can be picked up by Simulium
spp. that are constantly present. Vector control using
ground applications of Temephos, an insecticide with
low environmental hazards risk, has been used success-
fully in the west Africa by the Onchocerciasis control
programme, in the Equatorial Guinea (Bioko Island)
and Uganda by the African programme for Onchocer-
ciasis control [59, 60].
The impact of IVM intake was most readily reflected
in mf prevalence and intensity rather than nodule preva-
lence. No association between IVM intake and nodule
burden was found. This could be attributed to the fact
that ivermectin is a microfilaricidal drug and as such has
minor effects on adult worms in nodules hence the little
variations in nodule prevalence and intensity with treat-
ment [21, 61, 62]. In the savannah areas, there are data
both published and unpublished showing that nodule
rate reduces with the IVM MDA [63]. The persistent
nodule rate in this area, could also be explained by con-
tinuous transmission.
Another important point to stress on, is the fact that
no association between adherence to treatment and mf
prevalence and intensity was found in children. This
could imply that children are not as good as adults at
recalling the number of times they have taken the drug.
Also, they could have given wrong responses thinking
they would be blamed if they declared they had not been
taken the drug hence, the necessity of sensitising adoles-
cents (11 years and above) prior to using the approach
described in this paper. Adherence data for children
could also be obtained from parents or guardians of en-
rolled children [13]. For the present study, only children
less or equal to 10 years of age were assisted by their
parents or guardians assuming older individuals would
be able to give reliable responses.
Additional studies are required to understand the rea-
sons for non-adherence to MDA, to refine health educa-
tion message(s) to target the non-adherents, and to put
in place alternative approaches for crossing the finish
line. These might include vector control, mass treatment
with macrofilaricides if available or test and treat activ-
ities that permit selective treatment of people with re-
sidual infections. Data from the present study have
shown that knowledge of the adherence to MDA in a re-
gion could give a broad idea about the onchocerciasis
endemicity level in the area. Identifying communities of
greatest needs for control would constitute a prerequis-
ite for implementing the above-mentioned alternative
approaches for crossing the finish line. The approach de-
scribed herein could be a convenient non-invasive way
of achieving that task. This approach could also be used
to rapidly assess CDTI projects that had issues (SAEs)
at the onset or during the implementation of the con-
trol programme.
Conclusion
This study was designed to assess the relationship or as-
sociation between oral declaration on the adherence to
ivermectin treatment and the parasitological indicators
of the infection. It has revealed that adherence to iver-
mectin treatment is not adequate in this rain forest area
where L. loa also co-exists with O. volvulus. The preva-
lence and intensity of onchocerciasis remain high in in-
dividuals who have never taken ivermectin after more
than a decade of MDA. There was a significant negative
association between adherence to treatment and mf
prevalence and intensity. This was an indication that
participants’ oral declaration could be relied upon for
the evaluation of the impact of long term treatment of
onchocerciasis with ivermectin. However, there may be
need to refine this approach through validation in other
communities or context. There is need to implement al-
ternative strategies in settings like the one described in
this paper.
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